Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00296712 · ClinicalTrials.gov registry record · Phase 4
Are Two Antidepressants a Good Initial Treatment for Depression?
A Phase 4 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 55
- Enrollment target
NCT00296712 is a Phase 4 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 55 participants.
The verdict
NCT00296712, a Phase 4 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 55 participants
- Enrollment target
Study Summary
Relatively drug naive patients will receive two antidepressant medications as initial treatment.
Interventions
- DRUG escitalopram + bupropion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2005-02 |
| Est. Completion | 2006-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00296712
The ClinicalTrials.gov registry entry for NCT00296712 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which escitalopram + bupropion is the first listed.
NCT00296712 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00296712 about?
NCT00296712 is a clinical study titled "Are Two Antidepressants a Good Initial Treatment for Depression?". Relatively drug naive patients will receive two antidepressant medications as initial treatment.
What is the current status of trial NCT00296712?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 55 participants. The study started on 2005-02. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00296712?
The interventions under investigation include: escitalopram + bupropion (DRUG).
Who is sponsoring clinical trial NCT00296712?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.